| 13.6 -2.51 (-15.58%) | 12-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases. PRS-220: An orally inhaled Anticalin protein designed to target connective tissue growth factor, intended for the treatment of idiopathic pulmonary fibrosis (IPF). Immuno-Oncology: Cinrebafusp alfa: A bispecific drug targeting both 4-1BB and HER2, developed for gastric cancers that express high or low levels of HER2. PRS-344/S095012: A bispecific Anticalin-antibody fusion protein in Phase I clinical trials, targeting 4-1BB and PD-L1 for various immuno-oncology indications. PRS-352: A preclinical-stage program focusing on undisclosed targets within immuno-oncology. Pieris has established several strategic partnerships, including collaboration and licensing agreements with Les Laboratoires Servier (and Institut de Recherches Internationales Servier), AstraZeneca AB, and Seagen Inc. Further licensing agreements are in place with the Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Additionally, the company has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Established in 2000, Pieris Pharmaceuticals, Inc. maintains its headquarters in Boston, Massachusetts.
Thu, 17 Oct 2024
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - citybiz
Thu, 15 Aug 2024
Inside the deal: How Palvella Therapeutics plans to go public through a reverse merger with a Boston pharma firm - The Business Journals
Wed, 14 Aug 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - PR Newswire
Thu, 25 Apr 2024
Pieris Pharmaceuticals (NASDAQ: PIRS) - Share Price - intelligentinvestor.com.au
Sat, 04 Mar 2023
Michael Richman Net Worth (2026) - GuruFocus
Thu, 04 Aug 2022
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|